1
|
El Marrahi A, Lipreri F, Kang Z, Gsell L, Eroglu A, Alber D, Hausser J. NIPMAP: niche-phenotype mapping of multiplex histology data by community ecology. Nat Commun 2023; 14:7182. [PMID: 37935691 PMCID: PMC10630431 DOI: 10.1038/s41467-023-42878-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 10/24/2023] [Indexed: 11/09/2023] Open
Abstract
Advances in multiplex histology allow surveying millions of cells, dozens of cell types, and up to thousands of phenotypes within the spatial context of tissue sections. This leads to a combinatorial challenge in (a) summarizing the cellular and phenotypic architecture of tissues and (b) identifying phenotypes with interesting spatial architecture. To address this, we combine ideas from community ecology and machine learning into niche-phenotype mapping (NIPMAP). NIPMAP takes advantage of geometric constraints on local cellular composition imposed by the niche structure of tissues in order to automatically segment tissue sections into niches and their interfaces. Projecting phenotypes on niches and their interfaces identifies previously-reported and previously-unreported spatially-driven phenotypes, concisely summarizes the phenotypic architecture of tissues, and reveals fundamental properties of tissue architecture. NIPMAP is applicable to both protein and RNA multiplex histology of healthy and diseased tissue. An open-source R/Python package implements NIPMAP.
Collapse
Affiliation(s)
- Anissa El Marrahi
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
- SciLifeLab; Solna, Stockholm, 171 65, Sweden
| | - Fabio Lipreri
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
- SciLifeLab; Solna, Stockholm, 171 65, Sweden
| | - Ziqi Kang
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
- SciLifeLab; Solna, Stockholm, 171 65, Sweden
| | - Louise Gsell
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
- SciLifeLab; Solna, Stockholm, 171 65, Sweden
| | - Alper Eroglu
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
- SciLifeLab; Solna, Stockholm, 171 65, Sweden
| | - David Alber
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden
- SciLifeLab; Solna, Stockholm, 171 65, Sweden
| | - Jean Hausser
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden.
- SciLifeLab; Solna, Stockholm, 171 65, Sweden.
| |
Collapse
|
2
|
An Overview of Peptide-Based Molecules as Potential Drug Candidates for Multiple Sclerosis. Molecules 2021; 26:molecules26175227. [PMID: 34500662 PMCID: PMC8434400 DOI: 10.3390/molecules26175227] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 07/27/2021] [Accepted: 08/04/2021] [Indexed: 12/14/2022] Open
Abstract
Multiple sclerosis (MS) belongs to demyelinating diseases, which are progressive and highly debilitating pathologies that imply a high burden both on individual patients and on society. Currently, several treatment strategies differ in the route of administration, adverse events, and possible risks. Side effects associated with multiple sclerosis medications range from mild symptoms, such as flu-like or irritation at the injection site, to serious ones, such as progressive multifocal leukoencephalopathy and other life-threatening events. Moreover, the agents so far available have proved incapable of fully preventing disease progression, mostly during the phases that consist of continuous, accumulating disability. Thus, new treatment strategies, able to halt or even reverse disease progression and specific for targeting solely the pathways that contribute to the disease pathogenesis, are highly desirable. Here, we provide an overview of the recent literature about peptide-based systems tested on experimental autoimmune encephalitis (EAE) models. Since peptides are considered a unique therapeutic niche and important elements in the pharmaceutical landscape, they could open up new therapeutic opportunities for the treatment of MS.
Collapse
|
3
|
Richardson N, Wraith DC. Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity. IMMUNOTHERAPY ADVANCES 2021; 1:ltab009. [PMID: 35919740 PMCID: PMC9327121 DOI: 10.1093/immadv/ltab009] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 03/28/2021] [Accepted: 05/21/2021] [Indexed: 12/11/2022] Open
Abstract
Targeted restoration of immunological tolerance to self-antigens or innocuous environmental allergens represents the ultimate aim of treatment options in autoimmune and allergic disease. Antigen-specific immunotherapy (ASI) is the only intervention that has proven disease-modifying efficacy as evidenced by induction of long-term remission in a number of allergic conditions. Mounting evidence is now indicating that specific targeting of pathogenic T cells in autoinflammatory and autoimmune settings enables effective restoration of immune homeostasis between effector and regulatory cells and alters the immunological course of disease. Here, we discuss the key lessons learned during the development of antigen-specific immunotherapies and how these can be applied to inform future interventions. Armed with this knowledge and current high-throughput technology to track immune cell phenotype and function, it may no longer be a matter of ‘if’ but ‘when’ this ultimate aim of targeted tolerance restoration is realised.
Collapse
Affiliation(s)
- Naomi Richardson
- Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
| | - David Cameron Wraith
- Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
| |
Collapse
|
4
|
Lee MJ, Jang Y, Han J, Kim SJ, Ju X, Lee YL, Cui J, Zhu J, Ryu MJ, Choi SY, Chung W, Heo C, Yi HS, Kim HJ, Huh YH, Chung SK, Shong M, Kweon GR, Heo JY. Endothelial-specific Crif1 deletion induces BBB maturation and disruption via the alteration of actin dynamics by impaired mitochondrial respiration. J Cereb Blood Flow Metab 2020; 40:1546-1561. [PMID: 31987007 PMCID: PMC7308523 DOI: 10.1177/0271678x19900030] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Cerebral endothelial cells (ECs) require junctional proteins to maintain blood-brain barrier (BBB) integrity, restricting toxic substances and controlling peripheral immune cells with a higher concentration of mitochondria than ECs of peripheral capillaries. The mechanism underlying BBB disruption by defective mitochondrial oxidative phosphorylation (OxPhos) is unclear in a mitochondria-related gene-targeted animal model. To assess the role of EC mitochondrial OxPhos function in the maintenance of the BBB, we developed an EC-specific CR6-interactin factor1 (Crif1) deletion mouse. We clearly observed defects in motor behavior, uncompacted myelin and leukocyte infiltration caused by BBB maturation and disruption in this mice. Furthermore, we investigated the alteration in the actin cytoskeleton, which interacts with junctional proteins to support BBB integrity. Loss of Crif1 led to reorganization of the actin cytoskeleton and a decrease in tight junction-associated protein expression through an ATP production defect in vitro and in vivo. Based on these results, we suggest that mitochondrial OxPhos is important for the maturation and maintenance of BBB integrity by supplying ATP to cerebral ECs.
Collapse
Affiliation(s)
- Min Joung Lee
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Yunseon Jang
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Jeongsu Han
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea
| | - Soo J Kim
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Xianshu Ju
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Yu Lim Lee
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Jianchen Cui
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Jiebo Zhu
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Min Jeong Ryu
- Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea
| | - Song-Yi Choi
- Department of Pathology, Chungnam National University, Daejeon, Republic of Korea
| | - Woosuk Chung
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Anesthesiology and Pain Medicine, School of Medicine, Chungnam National University, Daejeon, Republic of Korea.,Department of Anesthesiology and Pain medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Chaejeong Heo
- Center for Integrated Nanostructure Physics (CINAP), Institute for Basic Science (IBS), Suwon, South Korea.,Center for Neuroscience Imaging Research (CNIR), Institute for Basic Science (IBS), Suwon, South Korea
| | - Hyon-Seung Yi
- Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Hyun Jin Kim
- Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Yang H Huh
- Electron Microscopy Research Center, Korea Basic Science Institute, Cheongju, Chungcheongbukdo, Republic of Korea
| | - Sookja K Chung
- Medical Faculty at Macau University of Science and Technology, Taipa, Macau
| | - Minho Shong
- Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.,Research Center for Endocrine and Metabolic Diseases, Chungnam National University School of Medicine, Daejeon, Republic of Korea
| | - Gi-Ryang Kweon
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea
| | - Jun Young Heo
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.,Department of Biochemistry, Chungnam National University, Daejeon, Republic of Korea.,Infection Control Convergence Research Center, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| |
Collapse
|
5
|
De Souza ALS, Rudin S, Chang R, Mitchell K, Crandall T, Huang S, Choi JK, Okitsu SL, Graham DL, Tomkinson B, Dellovade T. ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs. Neurol Ther 2018. [PMID: 29542041 PMCID: PMC5990509 DOI: 10.1007/s40120-018-0094-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
Introduction Antigen-specific immunotherapy could provide a targeted approach for the treatment of multiple sclerosis that removes the need for broad-acting immunomodulatory drugs. ATX-MS-1467 is a mixture of four peptides identified as the main immune-dominant disease-associated T-cell epitopes in myelin basic protein (MBP), an autoimmune target for activated autoreactive T cells in multiple sclerosis. Previous animal studies have shown that ATX-MS-1467 treatment prevented the worsening of signs of disease in experimental autoimmune encephalitis (EAE) in the humanized (DR2 × Ob1)F1 mouse in a dose-dependent fashion. Methods and Results Our study extends these observations to show that subcutaneous treatment with 100 µg of ATX-MS-1467 after induction of EAE in the same mouse model reversed established clinical disability (p < 0.0001) and histological markers of inflammation and demyelination (p < 0.001) compared with vehicle-treated animals; furthermore, in longitudinal magnetic resonance imaging analyses, disruption of blood–brain barrier integrity was reversed, compared with vehicle-treated animals (p < 0.05). Chronic treatment with ATX-MS-1467 was associated with an enduring shift from a pro-inflammatory to a tolerogenic state in the periphery, as shown by an increase in interleukin 10 secretion, relative to interleukin 2, interleukin 17 and interferon γ, a decrease in splenocyte proliferation and an increase in interleukin 10+ Foxp3− T cells in the spleen. Conclusion Our results suggest that ATX-MS-1467 can induce splenic iTregs and long-term tolerance to MBP with the potential to partially reverse the pathology of multiple sclerosis, particularly during the early stages of the disease. Funding EMD Serono, Inc., a business of Merck KGaA.
Collapse
Affiliation(s)
- Adriano Luís Soares De Souza
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA.
| | - Stefan Rudin
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Rui Chang
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Keith Mitchell
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Timothy Crandall
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Shuning Huang
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Ji-Kyung Choi
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA
| | - Shinji L Okitsu
- TIP Immunology, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Danielle L Graham
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Blake Tomkinson
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| | - Tammy Dellovade
- Neurology eTIP, Translational and Biomarker Research Group, EMD Serono Research and Development Institute, Inc., Billerica, MA, USA
| |
Collapse
|
6
|
Streeter HB, Rigden R, Martin KF, Scolding NJ, Wraith DC. Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS. NEUROLOGY(R) NEUROIMMUNOLOGY & NEUROINFLAMMATION 2015; 2:e93. [PMID: 25798453 PMCID: PMC4360798 DOI: 10.1212/nxi.0000000000000093] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Accepted: 02/10/2015] [Indexed: 12/18/2022]
Abstract
OBJECTIVE The study was designed to test the efficacy of ATX-MS-1467 in a relevant preclinical model and to assess its safety for the treatment of patients with secondary progressive multiple sclerosis (SPMS). METHODS ATX-MS-1467 was tested for its ability to suppress experimental autoimmune encephalomyelitis (EAE) in the (Ob x DR2)F1 mouse both before and after disease onset. Safety was assessed by clinical assessment, MRI analysis, and the measurement of immune responses to self- and nonself-antigens in patients with SPMS. RESULTS ATX-MS-1467 displayed a dose-dependent inhibition of EAE and was more effective than glatiramer acetate in the treatment of ongoing disease in humanized mice. A phase 1 open-label dose-escalating study demonstrated that ATX-MS-1467 was safe and well-tolerated in a group of 6 patients with SPMS, up to a dose of 800 µg. CONCLUSIONS The results of this study support further development of ATX-MS-1467 in a clinical trial powered to investigate the immunologic and clinical benefits of treatment in relapsing-remitting MS. CLASSIFICATION OF EVIDENCE This study provides Class IV evidence that ATX-MS-1467 is safe and tolerated in a group of 6 patients with SPMS.
Collapse
Affiliation(s)
- Heather B Streeter
- Apitope Technology Bristol Ltd. (H.B.S., R.R., K.F.M., D.C.W.), Bristol UK; School of Cellular and Molecular Medicine (H.B.S., D.C.W.) and School of Clinical Sciences (N.J.S.), University of Bristol, UK; and Southmead Hospital (N.J.S.), Bristol, UK
| | - Rachel Rigden
- Apitope Technology Bristol Ltd. (H.B.S., R.R., K.F.M., D.C.W.), Bristol UK; School of Cellular and Molecular Medicine (H.B.S., D.C.W.) and School of Clinical Sciences (N.J.S.), University of Bristol, UK; and Southmead Hospital (N.J.S.), Bristol, UK
| | - Keith F Martin
- Apitope Technology Bristol Ltd. (H.B.S., R.R., K.F.M., D.C.W.), Bristol UK; School of Cellular and Molecular Medicine (H.B.S., D.C.W.) and School of Clinical Sciences (N.J.S.), University of Bristol, UK; and Southmead Hospital (N.J.S.), Bristol, UK
| | - Neil J Scolding
- Apitope Technology Bristol Ltd. (H.B.S., R.R., K.F.M., D.C.W.), Bristol UK; School of Cellular and Molecular Medicine (H.B.S., D.C.W.) and School of Clinical Sciences (N.J.S.), University of Bristol, UK; and Southmead Hospital (N.J.S.), Bristol, UK
| | - David C Wraith
- Apitope Technology Bristol Ltd. (H.B.S., R.R., K.F.M., D.C.W.), Bristol UK; School of Cellular and Molecular Medicine (H.B.S., D.C.W.) and School of Clinical Sciences (N.J.S.), University of Bristol, UK; and Southmead Hospital (N.J.S.), Bristol, UK
| |
Collapse
|
7
|
Wraith DC, Nicholson LB. The adaptive immune system in diseases of the central nervous system. J Clin Invest 2012; 122:1172-9. [PMID: 22466659 DOI: 10.1172/jci58648] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Tissues of the CNS, such as the brain, optic nerves, and spinal cord, may be affected by a range of insults including genetic, autoimmune, infectious, or neurodegenerative diseases and cancer. The immune system is involved in the pathogenesis of many of these, either by causing tissue damage or alternatively by responding to disease and contributing to repair. It is clearly vital that cells of the immune system patrol the CNS and protect against infection. However, in contrast to other tissues, damage caused by immune pathology in the CNS can be irreparable. The nervous and immune systems have, therefore, coevolved to permit effective immune surveillance while limiting immune pathology. Here we will consider aspects of adaptive immunity in the CNS and the retina, both in the context of protection from infection as well as cancer and autoimmunity, while focusing on immune responses that compromise health and lead to significant morbidity.
Collapse
Affiliation(s)
- David C Wraith
- School of Clinical Sciences, University of Bristol, Bristol, United Kingdom.
| | | |
Collapse
|
8
|
Mazza G, Sabatos-Peyton CA, Protheroe RE, Herman A, Campbell JD, Wraith DC. Isolation and characterization of human interleukin-10-secreting T cells from peripheral blood. Hum Immunol 2010; 71:225-34. [PMID: 20034527 DOI: 10.1016/j.humimm.2009.12.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2009] [Revised: 11/30/2009] [Accepted: 12/12/2009] [Indexed: 10/20/2022]
Abstract
Recent studies have expanded our understanding of the role of the anti-inflammatory cytokine interleukin (IL)-10, produced by multiple lineages of both human and murine T cells, in regulating the immune response. Here, we demonstrate that the small percentage of circulating CD4(+) T cells that secrete IL-10 can be isolated from human peripheral blood and, importantly, we have optimized a protocol to expand these cells in both antigen-specific and polyclonal manners. Expanded CD4(+)IL-10(+) T cells abrogate proliferation and T helper (Th) 1-like cytokine production in an antigen-specific manner, and to a lesser extent exhibit bystander suppressive capacity. CD4(+)IL-10(+) T cells are suppressive in a cell contact-dependent way, though they do not require secretion of IL-10 for their suppressive role in vitro. CD4(+)IL-10(+) T cells have an activated phenotype, with high expression of CD25, CD69, and cytotoxic T-lymphocyte antigen-4, and are largely FoxP3 negative. This novel method for the isolation and expansion of suppressive IL-10-secreting T cells has important implications both for further research and clinical therapeutic development.
Collapse
Affiliation(s)
- Graziella Mazza
- Department of Cellular and Molecular Medicine, University of Bristol, School of Medical Sciences, University Walk, Clifton, Bristol, United Kingdom
| | | | | | | | | | | |
Collapse
|
9
|
Abstract
Autoreactive T cell responses have a crucial role in central nervous system (CNS) diseases such as multiple sclerosis. Recent data indicate that CNS autoimmunity can be mediated by two distinct lineages of CD4+ T cells that are defined by the production of either interferon-gamma or interleukin-17. The activity of these CD4+ T cell subsets within the CNS influences the pathology and clinical course of disease. New animal models show that myelin-specific CD8+ T cells can also mediate CNS autoimmunity. This Review focuses on recent progress in delineating the pathogenic mechanisms, regulation and interplay between these different T cell subsets in CNS autoimmunity.
Collapse
Affiliation(s)
- Joan Goverman
- Department of Immunology, University of Washington, Seattle, Washington 98195-7650, USA.
| |
Collapse
|
10
|
Nicolson K, Wraith D. Natural and induced regulatory T cells: targets for immunotherapy of autoimmune disease and allergy. INFLAMMATION & ALLERGY DRUG TARGETS 2006; 5:141-8. [PMID: 16918477 PMCID: PMC2629541 DOI: 10.2174/187152806778256098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Recent advances in immunology have greatly increased our understanding of immunological tolerance. In particular, there has been a resurgence of interest in mechanisms of immune regulation. Immune regulation refers to the phenomenon, previously known as immune suppression, by which excessive responses to infectious agents and hypersensitivities to otherwise innocuous antigens such as self antigens and allergens are avoided. We now appreciate that various distinct cell types mediate immune suppression and that some of these may be induced by appropriate administration of antigens, synthetic peptides and drugs of various types. The induction of antigen specific immunotherapy for treatment of autoimmune and allergic diseases remains the 'holy grail' for treatment of these diseases. This goal comes ever closer as understanding of the mechanisms of immune suppression and in particular antigen specific immunotherapy increases. Here we review evidence that immune suppression is mediated by various different subsets of CD4 T cells.
Collapse
Affiliation(s)
- K.S. Nicolson
- Department of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD., UK
| | - D.C. Wraith
- Department of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD., UK
| |
Collapse
|
11
|
Kawakami N, Odoardi F, Ziemssen T, Bradl M, Ritter T, Neuhaus O, Lassmann H, Wekerle H, Flügel A. Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. THE JOURNAL OF IMMUNOLOGY 2005; 175:69-81. [PMID: 15972633 DOI: 10.4049/jimmunol.175.1.69] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We embedded green fluorescent CD4(+) T cells specific for myelin basic protein (MBP) (T(MBP-GFP) cells) in the immune system of syngeneic neonatal rats. These cells persisted in the animals for the entire observation period spanning >2 years without affecting the health of the hosts. They maintained a memory phenotype with low levels of L-selectin and CD45RC, but high CD44. Although persisting in low numbers (0.01-0.1% of lymph node cells) they were sufficient to raise susceptibility toward clinical autoimmune disease. Immunization with MBP in IFA induced CNS inflammation and overt clinical disease in animals carrying neonatally transferred T(MBP-GFP) cells, but not in controls. The onset of the clinical disease coincided with mass infiltration of T(MBP-GFP) cells into the CNS. In the periphery, following the amplification phase a rapid contraction of the T cell population was observed. However, elevated numbers of fully reactive T(MBP-GFP) cells remained in the peripheral immune system after acute experimental autoimmune encephalomyelitis mediating reimmunization-induced disease relapses.
Collapse
Affiliation(s)
- Naoto Kawakami
- Department of Neuroimmunology, Max-Planck-Institute for Neurobiology, Martinsried, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Sundstedt A, O'Neill EJ, Nicolson KS, Wraith DC. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2003; 170:1240-8. [PMID: 12538682 DOI: 10.4049/jimmunol.170.3.1240] [Citation(s) in RCA: 180] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Regulatory CD4(+) T cells were induced in the Tg4 TCR transgenic mouse specific for the N-terminal peptide (Ac1-9) of myelin basic protein by intranasal administration of a high-affinity MHC-binding analog (Ac1-9[4Y]). Peptide-induced tolerant cells (PItol) were anergic, failed to produce IL-2, but responded to Ag by secretion of IL-10. PItol cells were predominantly CD25(-) and CTLA-4(+) and their anergic state was reversed by addition of IL-2 in vitro. PItol cells suppressed the response of naive Tg4 cells both in vitro and in vivo. The in vitro suppression mediated by these cells was not reversed by cytokine neutralization and was cell-cell contact-dependent. However, suppression of proliferation and IL-2 production by PItol cells in vivo was abrogated by neutralization of IL-10. These results emphasize an important role for IL-10 in the function of peptide-induced regulatory T cells in vivo and highlight the caution required in extrapolating mechanisms of T regulatory cell function from in vitro studies.
Collapse
Affiliation(s)
- Anette Sundstedt
- Department of Pathology and Microbiology, University of Bristol Medical School, Bristol, United Kingdom.
| | | | | | | |
Collapse
|
13
|
Barth H, Klein K, Börtlein A, Guseo A, Berg PA, Wiethölter H, Klein R. Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced T H1, relapsing-remitting course with enhanced T H0 reactivity. J Neuroimmunol 2002; 133:175-83. [PMID: 12446020 DOI: 10.1016/s0165-5728(02)00355-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In this study, we analysed the recall antigen-induced cytokine production by peripheral blood mononuclear cells (PBMC) from 31 patients with multiple sclerosis (MS) with a relapsing-remitting (rr) and a relapsing-progressive (rp) course and from 40 healthy controls. Cells were stimulated with purified protein derivative (PPD; type 1 response) and tetanus toxoid (TT; type 2 response). Cytokines were determined in the supernatants by ELISA. One of the interesting findings was that healthy controls showed more frequently an IL-5 production after incubation with TT than MS-patients (68% vs.37%; p<0.01), while the type 1 reactivity was only slightly enhanced in MS patients as compared to the controls. However, within the MS patients, there was a significant difference in the incidence of the type 1 reactivity comparing patients with an rp and an rr course (60% vs. 24%; p<0.05). Furthermore, the frequency of a type 0 profile (simultaneous PPD-induced IFN-gamma and TT-induced IL-5 production) was fourfold higher in rr than in the rp patients (43% vs. 10%, p<0.05). In vitro analysis of cytokine profiles in MS could therefore be an interesting approach to evaluate the prognosis of MS (rr vs. rp) already at the beginning of the disease. Thus, it seems that the presence of a type 0 profile is a valid indicator for a favorable course, while a type 1 profile is rather associated with rp MS.
Collapse
Affiliation(s)
- H Barth
- Medizinische Klinik, Innere Medizin II, Universität Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany
| | | | | | | | | | | | | |
Collapse
|
14
|
Mazza G, Ponsford M, Lowrey P, Campbell MJ, Zajicek J, Wraith DC. Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals. Clin Exp Immunol 2002; 128:538-47. [PMID: 12067310 PMCID: PMC1906251 DOI: 10.1046/j.1365-2249.2002.01831.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
It is generally accepted that multiple sclerosis (MS) is mediated by autoreactive T cells and that myelin basic protein (MBP) is one of the target autoantigens. The T-cell response to MBP has been analysed extensively, largely through the use of T-cell lines (TCL) and T-cell clones (TCC), and to date, three immunodominant regions (13-32, 84-103 and 144-163) have been described. However, given that TCL may represent a skewed pattern of peptide reactivity, we have developed a kinetic response assay in which the proliferation of peripheral blood mononuclear cells (PBMC) from MS patients and healthy individuals was measured directly against a panel of peptides spanning the full length of human MBP. Furthermore, PBMC from each subject were tested three times over the course of 18 months. A high proportion of MS patients exhibited a significant response to eight MBP regions (1-24, 30-54, 75-99, 90-114, 105-129, 120-144, 135-159 and 150-170). TCC were subsequently generated from MS subjects and were used to further define the epitope recognized in each case. Overall, normal individuals recognized significantly fewer peptides. In addition, we noted that the T-cell recognition of any one peptide can fluctuate, appearing at one time point, regressing, and subsequently reappearing at a later date. This study provides new insight into the recognition profile and dynamics of myelin-antigen-specific T cells in MS.
Collapse
Affiliation(s)
- G Mazza
- Department of Pathology and Microbiology, School of Medical Sciences, University of Bristol, UK.
| | | | | | | | | | | |
Collapse
|